Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Daniele Focosi and Irma Convertino.
Daniele Focosi
Connection Strength
0.961
Irma Convertino
  1. An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. Expert Opin Drug Discov. 2021 12; 16(12):1403-1414.
    View in: PubMed
    Score: 0.240
  2. Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs. Br J Clin Pharmacol. 2021 05; 87(5):2186-2188.
    View in: PubMed
    Score: 0.228
  3. Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients. Crit Care. 2020 06 11; 24(1):331.
    View in: PubMed
    Score: 0.222
  4. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline. MAbs. 2020 Jan-Dec; 12(1):1854149.
    View in: PubMed
    Score: 0.215
  5. The Impact of the COVID-19 "Infodemic" on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug Saf. 2020 08; 43(8):699-709.
    View in: PubMed
    Score: 0.056
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.